31 results about "Tissue biopsy" patented technology

The invention discloses stomach wall tissue biopsy forceps under a laparoscope, and belongs to the technical field of medical instruments. The biopsy forceps aim at solving the problems that existing biopsy forceps are low in sampling efficiency and inconvenient in angle adjustment. The device comprises a fixed pipe and a rotating pipe, a first pull rod is slidably connected into the fixed pipe, a second pull rod is slidably connected into the rotating pipe, an extension column is integrally formed at one end of the second pull rod, a limiting ball is integrally formed at one end of the extension column, and a limiting groove matched with the extension column and the limiting ball is formed in one end of the first pull rod; a connecting part is arranged between the fixed pipe and the rotating pipe and is used for connecting the fixed pipe and the rotating pipe; biopsy forceps are installed at the end, away from the fixed tube, of the rotating tube, and the biopsy forceps and the rotating tube rotate through a connecting part. The driving part is arranged at one end of the fixing tube and used for driving the first pull rod to move, a plurality of samples can be taken through one-time insertion, angle adjustment is flexible, operation is labor-saving, and the device is used for stomach wall tissue sampling under a laparoscope.

Methods are provided for detecting gene deletions and driver mutations using tumor-specific methylation patterns from cell-free DNA and tissue biopsies. The methods exploit the mutual exclusivity between tumor-specific methylation and homozygous gene deletion, enabling detection through absence of expected methylation signals. Applications include detection of MTAP, PTEN, and RB1 deletions, as well as prediction of EGFR single nucleotide (SNV) and small (up to 50 base pair) insertions and deletions (indel) driver mutations, enabling identification of patients eligible for targeted therapies.

A novel portable, and attachable device allows precise positioning of micro-tissues, tumor spheroids, and other biological samples during bioprinting. The device features an interchangeable connector for handling samples of various sizes and uses a manually adjustable pressure system for suction and deposition. A programmable control unit coordinates pressure and positioning based on input commands, enhancing accuracy and consistency in tissue handling. Compatible with multiple bioprinter systems and supporting both manual and automated operation, it streamlines workflows and improves user experience. This device addresses challenges in high-throughput biological positioning, critical for tissue engineering, clinical, pharmaceutical, and research applications. It supports advancements in customized medicine, biological models, and environmental monitoring, meeting the growing demand for precise biologic handling in the multi-billion-dollar bioprinting and biopsy markets. The device offers superior control over tissue biopsy positioning compared to current manual devices reliant on operator skill.

Methods for determining genomic variant clonality using multi-region sequencing assays and algorithms are described. For example, the methods can include receiving, at one or more processors, sequence read data for a sample obtained from a subject. The sequence read data is obtained from nucleic acid molecules (extracted, e.g., via needle punch) from a plurality of target regions within the sample (e.g., spatially distinct regions of a tissue biopsy sample). For each target region within the sample, a set of reads from the sequence read data associated with the respective target region is identified, then a presence of a candidate genomic variant within the target region is detected based on the set of reads. A total number of target regions in which the presence of the candidate genomic variant is compared to a first predetermined threshold. Based on the comparison, clonality of the candidate genomic variant is determined.

The application discloses a low-noise pneumatic air gun type biopsy needle convenient for single-hand loading, which comprises an inner needle, an outer needle, a connector, a mechanical valve, a firing mechanism, a loading mechanism, a needle cylinder, a needle cylinder shell, a first piston, a tension spring, a second piston and a compression spring. The inner needle is glued on the outer side of the front end of the needle cylinder, the outer needle is glued on one end of the connector and is sleeved on the outer side of the inner needle, and the other end of the connector is fixed with the elongated part of the second piston. The needle cylinder comprises a needle cylinder part one and a needle cylinder part two, and the needle cylinder and the needle cylinder shell are bonded into an integrated whole after being aligned. The second piston is fixedly connected with the compression spring and is located on the inner side of the front end of the needle cylinder, and the other end of the compression spring is sleeved on the protruding part on the inner side of the front end of the needle cylinder. The first piston is fixedly connected with the tension spring and is located on the inner side of the tail end of the needle cylinder, and the other end of the tension spring is bonded with the tail seat of the needle cylinder. The firing mechanism realizes button control of cutting and sampling of the outer needle. The loading mechanism realizes button control of returning and loading of the outer needle. The application reduces the dependence of surgical operation on the experience of doctors, reduces the noise generated in the surgical process, avoids the body displacement of patients due to the noise, improves the precision of tissue biopsy surgery, can realize single-hand operation and improves the convenience of surgical operation.

Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.

The invention relates to devices and methods for depth-selective tissue biopsy and segregation, tubular stricture dilation, mucosal ablation and resurfacing, and clinical agent administration using balloon devices, including devices for selective access to different depths of a target tissue.

The present disclosure relates generally to the field of medical devices. In particular, the present disclosure relates to medical systems and methods configured to shield the sharpened distal end of needles, such as exchangeable biopsy needles. The biopsy needles may be used for tissue biopsy and sampling under radial ultrasound guidance.

The invention discloses a kit for detecting circulating tumor DNA (deoxyribonucleic acid) of portal vein and branch vein blood of portal vein. The kit comprises: a nucleic acid extraction assembly comprising an optimized lysate and selectively bound magnetic beads; the library construction component comprises a terminal repair / tailing fusion enzyme and a Y-shaped linker with a molecular identifier; the targeted enrichment assembly comprises a specific primer group and a probe group and is used for enriching related gene targets of the abdominal organ tumors; and necessary reaction components. Through an optimized nucleic acid extraction method, an efficient library construction system and a precise targeted enrichment technology, high-sensitivity detection of low-abundance ctDNA in portal venous blood is achieved, and the lower detection limit reaches 0.1% of mutation allele frequency. The kit is particularly suitable for early diagnosis, curative effect monitoring and prognosis evaluation of abdominal organ tumors such as intestinal cancer, liver cancer and pancreatic cancer.

The application discloses a kind of methylation liquid biopsy model construction method and system of tuberculous granuloma and lung cancer based on multi-omics sequencing.Use the DNA and RNA data extracted from ex vivo lung tissue sample sequencing and combine blood data screening analysis to obtain methylation DNA data, then use machine learning classification model independent training to obtain methylation liquid biopsy model;System contains gene extraction equipment, second-generation high-throughput sequencer, blood testing equipment and computer, computer will be off data and blood data together into computer comprehensive screening to obtain methylation DNA data, then construct model and predict to obtain the biopsy result of tuberculous granuloma and lung cancer.The application can realize the high-precision, non-invasive detection of tuberculous granuloma and lung cancer, can be flexibly selected according to specific needs, has the stability and reliability characteristics of marker, avoids the invasive risk of tissue biopsy, has wide applicability, and has important application value.

The present application relates to the field of medicine biotechnology, especially the application of RUNX2 as a marker in the preparation of a breast malignant phyllodes tumor diagnosis or detection reagent. The reagent can assist conventional biopsy according to the expression level of RUNX2 in different grades of breast phyllodes tumor, and can diagnose, differentially diagnose, grade and prognostically analyze the breast phyllodes tumor. The RUNX2 detection primer sequence and detection antibody of the present application are important components of the diagnosis or detection reagent or kit, so that the detection of breast malignant phyllodes tumor is more simple, fast and accurate, has good clinical application value, helps to further improve the diagnosis level of breast malignant phyllodes tumor, and is expected to become the first diagnosis and detection kit for breast malignant phyllodes tumor.

1. The name of the design product: electric bone tissue biopsy push handle. 2. The use of the design product: for electric bone tissue biopsy push handle. 3. The design features of the design product: in shape. 4. The picture or photo that best indicates the design features: perspective view.

The invention provides a system and a method for prospectively predicting the property of a thyroid nodule. The method comprises the following steps: an acquisition module is used for acquiring a tissue biopsy sample; the quantitative polymerase chain reaction detection module is used for detecting BRAF V600E information; the MRM MS detection module is used for detecting quantitative information of the peptide fragment; and the evaluation module is used for evaluating the property of the thyroid nodule by using a model for predicting the property of the thyroid nodule by taking the quantitative information of the final characteristic peptide fragment, the BRAF V600E information and the gender and age of the target subject as characteristic information. BRAF V600E mutation and the content of various polypeptides in a thyroid puncture sample are detected, the optimal feature combination is selected by using various machine learning means in combination with clinical information of gender, age and nodule size under ultrasound, a prediction model is established, the properties of thyroid nodules are evaluated and classified, clinicians are assisted in discriminating the thyroid nodules, and the accuracy of thyroid nodule identification is improved. Therefore, the problem of inaccurate diagnosis in clinic is relieved.

The present invention relates to a gene panel for predicting the responsiveness of renal cancer patients to radiotherapy. In the present invention, the responsiveness of patients to stereotactic body radiotherapy can be predicted with high accuracy by only biopsy of a small amount of tissue, thereby maximizing the efficiency of radiotherapy for patients with difficulty in surgery and at the same time, providing the advantage of preserving renal function.

The invention discloses a tumor immunotherapy curative effect prediction kit based on bone marrow spleen neutrophil proportion, which comprises an anti-human CD62L-PE antibody, an anti-human CD11b-PE-Cy7 antibody, an anti-human CD44-APC antibody and an anti-human ICAM1-FITC antibody which are respectively used for marking neutrophil subgroups in a peripheral blood sample, and comprises a hemolytic agent which is used for removing red blood cells in the sample, according to the present invention, the structure is scientific and reasonable, the use is safe and convenient, the ratio of the bone marrow-derived neutrophil to the spleen-derived neutrophil, i.e. The M / S ratio, has the significant negative correlation with the treatment effect of the PD-1 inhibitor, and the kit designed based on the discovery can achieve the rapid and non-invasive immune response evaluation at the peripheral blood level, compared with an existing method depending on tissue biopsy or PD-L1 immunohistochemistry, the method has the advantages that the immune microenvironment state of a patient can be reflected more early and dynamically, and a precise curative effect prediction basis is provided for a PD-1 / PD-L1 inhibitor and a combination therapy thereof.

A method and system of identification and characterisation of histological features of bowel disease are disclosed. The method and system quantify inflammatory indicators and changes in tissue architecture. Spatial identification and measurement of attributes in IBD tissue biopsies are used for insight into disease activity.

Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer. In some embodiments, the disclosure provides improved prostate antigen standards for quantifying levels of prostate antigens.

The application discloses a cavity tissue biopsy guiding device and method based on optical fiber imaging and state identification, and belongs to the technical field of optical fiber imaging, medical image analysis and endoscope biopsy guiding. The device comprises a light source module, a modulation module, an optical fiber probe, a biopsy forceps, a calibration module, an imaging module, a dynamic calibration module and a computer. The optical fiber probe is inserted into the biopsy forceps channel and extends out of the forceps opening area to scan and image the target tissue; the calibration module measures the transmission matrix, the dynamic calibration module performs dynamic calibration based on the reflection signal, and the computer completes image reconstruction, tissue state identification and sampling prompt generation. According to the spatial correlation between the imaging area and the biopsy area, the method outputs sampling prompt information to assist in target area biopsy sampling, and improves the pertinence, accuracy and reliability of biopsy positioning.

The invention provides Salivary Biomarker Panel for Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, comprising synergistic combination of miR-1307-5p, CD44v6, KRT4, and PD-L1 quantified from salivary extracellular vesicles. Biomarker expression values are processed in which fold-change thresholds are computed, individual ChemoScore, RelapseScore, and ImmunoScore are derived, and patients are stratified into therapeutic response, relapse risk, immunotherapy suitability, and prognostic categories. Individual scores are further integrated into Overall Risk Score to classify patients into low, moderate, high, or very high risk. Limitations of tissue biopsies and delayed imaging-based assessments are overcome, enabling repeatable, real-time molecular monitoring to support personalized treatment strategies. The panel embodies into diagnostic kit comprising reagents, primers, reference controls, integrated scoring system, facilitating standardized detection and interpretation for dynamic clinical decision-making in head and neck oncology.

Various disclosed embodiments include illustrative apparatuses, systems, and methods for providing a vacuum force during tissue biopsies. In an illustrative embodiment, an illustrative apparatus includes a housing that is attachable to a handle of a medical device and a piston device that is disposed at least partially within the housing. The piston device is configured to be biased in a first direction and lockable in a loaded pre-suction position.

The invention discloses a gastric cancer pathological tissue biopsy digital image analysis method, and relates to the field of image segmentation. The method mainly comprises the following steps: acquiring a pathological grayscale image; determining a first evaluation index according to the distribution deviation of the gray values in the connected domain; determining a second evaluation index according to the local saliency features at the pixel points in the connected domain and the overall gray level gradient trend; performing segmentation based on a comprehensive judgment index determined by the first evaluation index and the second evaluation index to obtain a region of interest; sequentially screening out a first type of regions and a second type of regions from all the regions of interest; dividing the second type of region into a low differentiation cell region and a suspected high differentiation cell region according to the area of the second type of region; and based on the local density of the pixel points in the suspected highly-differentiated cell region, segmenting the highly-differentiated cell region. According to the invention, region segmentation is carried out according to the wettability growth and shape features of the lesion region in the pathological grayscale image, and the segmentation precision of the pathological grayscale image is improved.

A method and device for detecting tissue fibrosis. The method includes: determining whether there is a possibility for tissue inflammation; and when there is a possibility for tissue inflammation, monitoring tissue stiffness or a parameter reflecting tissue stiffness during a treatment of the tissue inflammation to determine whether the tissue inflammation has been eliminated; when the tissue inflammation has been eliminated or there is no possibility for tissue inflammation, obtaining a degree of tissue fibrosis or information related to the degree of tissue fibrosis according to tissue stiffness or a parameter reflecting tissue stiffness. The embodiments enable the tracking of the tissue stiffness during the treatment of tissue inflammation to determine whether tissue inflammation has been eliminated or not, and since tissue stiffness can be detected by a non-invasive quantitative detection technique of tissue elastic modulus, avoiding defects caused by tissue biopsy.

The valve assembly comprises a connecting mechanism, a negative pressure source, a liquid source, a first valve and a second valve, the first valve and the second valve are arranged on the two sides of the connecting mechanism, the first valve is provided with a first inlet, a first outlet, a second inlet and a second outlet, and the second valve is provided with a second inlet and a second outlet. The second valve is provided with a third inlet and a third outlet, the negative pressure source is communicated with the first inlet and the second inlet, the liquid source is communicated with the third inlet, and the first outlet, the second outlet and the third outlet are suitable for being communicated with a catheter assembly of the tissue biopsy device. The first valve is arranged to selectively provide vacuum for the guide pipe assembly through the first outlet or the second outlet, the second valve is arranged to selectively provide liquid for the guide pipe assembly through the third outlet, and negative pressure of the first outlet and the second outlet and liquid control of the third outlet are achieved by controlling the first valve and the second valve. And the tissue biopsy device can be conveniently and accurately operated by personnel.

Various embodiments can relate to a tissue biopsy instrument in accordance with various embodiments. The tissue biopsy instrument can include a hollow tube having a distal end portion and a proximal end portion. The tissue biopsy instrument can also include a cutting device held within the distal end portion of the hollow tube.

The application relates to application of maximum allelic mutation abundance in predicting immunotherapy efficacy of mismatch repair protein-intact metastatic colorectal cancer, in particular to application of maximum allelic mutation abundance and a reagent or system for detecting maximum allelic mutation abundance in preparation of a system for predicting immunotherapy efficacy of mismatch repair protein-intact metastatic colorectal cancer. The application is the first to use baseline ctDNA maxVAF as an immunotherapy efficacy prediction marker, fills the blank in the field, better guides individualized clinical treatment, uses a peripheral blood sample, calculates peripheral blood circulation maximum allelic mutation abundance, the sample is convenient to obtain, does not need invasive tissue biopsy, and is highly accepted by patients.

Provided are a primer-probe set and kit for detecting the methylation of SLIT2 and ZNF154 genes, and the use thereof in the detection of hepatocellular carcinoma. The primer-probe set does not require an additional reference gene; and compared to a reference gene method, the primer-probe set avoids, by means of simultaneously detecting methylated and non-methylated targets, a result error caused by the common polyploidy effect in cancer cells. In addition, on the premise of ensuring the system performance, an amplicon is designed to be as short as possible to adapt to the characteristics of a short cfDNA fragment. It is verified that using the primer-probe combination to detect the methylation of SLIT2 and ZNF154 genes has good specificity and high sensitivity. The primer-probe set can be used as an effective supplement to imaging or tissue biopsy in the diagnosis of primary hepatocellular carcinoma.

The invention discloses ureter biopsy forceps with a negative pressure suction function, and belongs to the field of medical instruments. Comprising a biopsy operation cavity, a collection cavity is slidably connected into the biopsy operation cavity, a fixed forceps handle is fixedly connected to the outer side wall of the biopsy operation cavity, a thumb clamping groove is fixedly connected to the outer side wall of the fixed forceps handle, a rotating block is fixedly connected to the outer side wall of the collection cavity, and a rotatable forceps handle is arranged on the outer side wall of the rotating block. The outer side wall of the rotatable forceps handle is fixedly connected with a finger clamping groove; according to the ureter biopsy forceps with the negative pressure suction function, through multi-structure collaborative design, precise tumor fixation is achieved through a negative pressure suction system, tissue cutting is controlled through a thumb clamping groove, a biopsy sample is conducted to the negative pressure suction pipe through the communicating pipe and the sample retention cavity through negative pressure, and then the biopsy sample is collected. The core problems that traditional biopsy forceps are difficult to sample, small in sampling amount and shallow in sampling depth and need to go in and out of the body repeatedly can be obviously solved.

This invention provides the application of sIL-2R and CA19-9 as biomarkers in the preparation of prognostic assessment products for pancreatic ductal adenocarcinoma. This invention uses sIL-2R and CA19-9 as detection biomarkers, which can be obtained through routine preoperative blood tests, eliminating the need for invasive or high-cost examinations such as tissue biopsies or gene testing, making it suitable for widespread application in medical institutions at all levels. Compared to using only CA19-9 as a single biomarker, this invention, combined with sIL-2R, can identify high-risk patients with normal CA19-9 but elevated sIL-2R, overcoming the limitation of CA19-9's inapplicability in Lewis antigen-negative individuals. Furthermore, it provides prognostic information from the perspective of the immune microenvironment that CA19-9 cannot reflect, significantly improving the comprehensiveness and accuracy of prognostic assessment.

The tissue biopsy sample segmentation table with the projection sizing function comprises a table top on the lower portion and a projection sizing device located on the upper portion of the table top, the projection sizing device comprises a shell and a dimension line light projection component installed in the shell, and light emitted by the dimension line light projection component is projected to the upper surface of the table top to form dimension lines. According to the cutting table, light is projected from top to bottom, and dimension lines are formed on the surface of the table, so that a ruler does not need to be controlled by hands during sampling and cutting, a sample of a biopsy sample only needs to be placed on the table, the projected scale lines are counted according to the required dimension, and the sample is cut by a knife, and non-contact sizing is realized; and the graduated scale is not polluted and does not need to be cleaned, so that the cutting and sampling efficiency of the detected material can be greatly improved.

To provide appropriate treatment for liver cancer patients, we offer indicators of sensitivity to multi-kinase inhibitors. [Solution] The present invention provides a testing method, testing apparatus, and testing program that use the fat content in liver cancer tissue as an indicator of sensitivity to multi-kinase inhibitors. This makes it possible to predict the therapeutic effect of multi-kinase inhibitors and provide appropriate treatment to individual liver cancer patients. The fat content can be calculated from images of liver cancer tissue or signals for image display. Images include MRI images, CT images, ultrasound images, stained images of tissue biopsies, etc. Signals for image display include MR signals, etc. Examples of multi-kinase inhibitors include lenvatinib and sorafenib.